A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Phase 2 Completed 124 enrolled Allergan

NaSingle-groupOpen-labelTreatment

Summary

The objective of this study is to evaluate abicipar pegol for safety and treatment effects in participants with neovascular age-related macular degeneration (AMD).

Timeline

Start: 2018-05-25
Primary completion: 2019-02-27
Completion: 2019-02-27

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abicipar pegol	Protein / enzyme biologic	2 mg	Intravitreal

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Summary

Timeline

Drugs

Indications